Rituximab mechanism of action

Rituximab is a monoclonal antibody drug used to treat certain autoimmune diseases and cancers, used to treat non-Hodgkin lymphoma, chronic lymphocytic leukemia Blood disorders (non-elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis, and Epstein-Barr virus-positive mucocutaneous ulcers, given by slow intravenous infusion.

Rituximab is a monoclonal antibody. Rituximab products target the CD20antigen expressed on the surface of proBlymphocytes and matureBlymphocytes. Rituximab products mediate lysis of B cells after binding to CD20. Possible mechanisms of cytolysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). bcells are thought to play a role in the pathogenesis of rheumatoid arthritis (RA) and related chronic synovitis. In this case, B cells may play a role at multiple sites in the autoimmune/inflammatory process, including through the production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T cell activation and /or proinflammatory cytokine production. If you want to get more high-quality information, you can contact YaoDe. YaoDe will do its best to learn more about high-quality overseas drugs for you.